PTAB Rejects Samsung Challenge To Herceptin Patent
The Patent Trial and Appeal Board on Monday rejected a bid from Samsung Bioepis Co. Ltd. for review of a patent covering the cancer drug Herceptin, finding Samsung's arguments were essentially...To view the full article, register now.
Already a subscriber? Click here to view full article